Reuters logo
BRIEF-Galena Biopharma's GALE-301 well-tolerated based on primary analysis
2016年6月6日 / 晚上6点06分 / 1 年前

BRIEF-Galena Biopharma's GALE-301 well-tolerated based on primary analysis

June 6 (Reuters) - Galena Biopharma Inc :

* Galena Biopharma presents GALE-301 phase 1/2a primary analysis at the American Society Of Clinical Oncology Annual Meeting 2016

* Primary analysis of a phase I/IIa dose finding trial demonstrated that vaccine is well tolerated and immunogenic Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below